Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Mochida

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Mochida's Japan sales performance.

Q&A: Amar Urhekar

Q&A: Amar Urhekar

We worked together at McCann in Japan. Just before his 30th birthday, he was diagnosed with ALS.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront

A new era for UK-Japanese scientific research relations

A new era for UK-Japanese scientific research relations Japan’s healthcare needs. Japan’s healthcare economy has evolved immensely since WWII. ... Historically, Japan has struggled to recruit patients and conduct trials within its domestic population.

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition The company said its would leverage its presence in Japan and other Asia-Pacific markets to maximise the potential of bemarituzumab in the gastric cancer market.

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds Using this approach, the analysis found that five countries – Australia, Canada, Japan, the UK and the US – plus the European Union, that is made up of 27 member states, could share

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....